Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 779 • 2019 ACR/ARP Annual Meeting
The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants
Kaiyu Jiang ¹, Yungki Park ¹, Tarbell Evan ¹, Tao Liu ² and James N. Jarvis³, ¹University at Buffalo Jacobs School of Medicine, Buffalo, NY, ²Roswell Park Cancer Instiyute, Buffalo, NY, ³University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY
Background/Purpose: IL2RA has been identified as a JIA-associated risk locus using both candidate gene and genetic fine mapping approaches. However, numerous gene expression studies comparing…
Abstract Number: 1920 • 2019 ACR/ARP Annual Meeting
School Nurse Education for Juvenile Idiopathic Arthritis
W. Blaine Lapin¹, Carleigh Kutac ², Danielle Guttman-Lapin ³, Amanda Brown ², Eyal Muscal ² and Filiz Seeborg ², ¹Baylor College of Medicine, Connecticut Children's Medical Center, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Aldine Independent School District, Houston, TX
Background/Purpose: There is a paucity of literature on the challenges children with JIA face at school. Despite treatment advances, children with JIA often rate their…
Abstract Number: 2714 • 2019 ACR/ARP Annual Meeting
Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry
Melissa Mannion¹, Fenglong Xie ² and Timothy Beukelman ³, ¹University of Alabama at Birmingham, Alabama, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Inactive disease is the stated goal of treatment in juvenile idiopathic arthritis (JIA) and is typically measured by a composite score that combines several…
Abstract Number: 781 • 2019 ACR/ARP Annual Meeting
Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?
Charlene Foley¹, Achilleas Floudas ², Sharon Ansboro ², Mary Canavan ², Monika Biniecka ², Emma Jane MacDermott ³, Ronan Mullan ⁴, Gerry Wilson ⁵, Ursula Fearon ⁶ and Orla Killeen ⁷, ¹Great Ormond Street Hospital, London, Ireland, ²TBSI, Dublin, Ireland, ³OLCHC, Dublin, Ireland, ⁴Tallaght Hospital, Dublin, Ireland, ⁵UCD, Dublin, Ireland, ⁶TBSI, Dublin, ⁷National Centre for Paediatric Rheumatology (NCPR), Our Lady’s Children’s Hospital Crumlin (OLCHC), Dublin, Ireland
Background/Purpose: Down syndrome associated Arthritis (DA) is 20 times more common than JIA. It is an erosive, polyarticular RF negative arthritis with predominance in the…
Abstract Number: 1921 • 2019 ACR/ARP Annual Meeting
Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Gaëlle Chédeville¹, Michelle Batthish ², Roberta Berard ³, Roxana Bolaria ⁴, Alessandra Bruns ⁵, David Cabral ⁶, Ciaran Duffy ⁷, Kerstin Gerhold ⁸, Tommy Gerschman ⁶, Jean-Philippe Proulx-Gauthier ⁹, Alan Rosenberg ¹⁰, Dax Rumsey ¹¹, Heinrike Schmeling ¹², Natalie Shiff ¹³, Gordon Soon ¹⁴, Lori Tucker ¹⁵ and Jaime Guzman ⁶, ¹The Montreal Children's Hospital, McGill University, Montreal, Canada, ²McMaster University, Hamilton, Canada, ³Children's Hospital, London Health Sciences Centre, London, Canada, ⁴University of British Columbia, Victoria, BC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Université Laval, Québec, QC, Canada, ¹⁰University of Saskatchewan, Saskatoon, SK, Canada, ¹¹University of Alberta, Edmonton, AB, Canada, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹³University of Florida, Gainesville, FL, ¹⁴University of Toronto, Toronto, ON, Canada, ¹⁵British Columbia Children’s Hospital, Vancouver, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and many medications are available to control the disease. While physician-reported adverse…
Abstract Number: 2715 • 2019 ACR/ARP Annual Meeting
Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset
Ruth Costello¹, Janet McDonagh ², Will Dixon ¹, Kimme Hyrich ² and Jenny Humphreys ¹, ¹Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, ²Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom / NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common childhood onset inflammatory arthritis. The last estimates of incidence of this disease in the United Kingdom…
Abstract Number: 782 • 2019 ACR/ARP Annual Meeting
Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion
Erdal Sag¹, Selcan Demir ², Morten A. Nielsen ³, Malene Hvid ⁴, Egemen Turhan ⁵, Yelda Bilginer ², Seza Ozen ⁶ and Bent Deleuran ⁷, ¹Hacettepe University, Ankara, Turkey, ²Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey, ³Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁴Department of Biomedicine; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁵Department of Orthopedics and Traumatology, Hacettepe University, Ankara, Turkey, ⁶Hacettepe University Hospital, Ankara, Turkey, ⁷Department of Biomedicine; Department of Rheumatology, Aarhus University, Aarhus, Denmark
Background/Purpose: Activated T cells are involved in the pathogenesis of the synovitis in oligoarticular Juvenile Idiopathic Arthritis (o-JIA). T cell activation is counter-balanced via co-inhibitory…
Abstract Number: 1923 • 2019 ACR/ARP Annual Meeting
Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials
Hermine Brunner¹, Chen Chen ¹, Alberto Martini ², Graciela Espada ², Rik Joos ², Jonathan Akikusa ², Jeffrey Chaitow ², Maria Luz Gámir Gámir ², Yukiko Kimura ³, Christoph Rietschel ², Daniel Siri ², Elzbieta Smolewska ², Heinrike Schmeling ¹, Diane Brown ¹, Fabrizio De Benedetti ⁴, Daniel J. Lovell ⁵, Bin Huang ¹ and Nicolino Ruperto ², ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ³Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, ⁴Bambino Gesù Children’s Hospital, Rome, Italy, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati
Background/Purpose: Tocilizumab (TCZ) was approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) based on the results of…
Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Rebecca Overbury¹, Aimee Hersh ², CJ Inman ², Sara Stern ², Karen James ² and John Bohnsack ³, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…
Abstract Number: 785 • 2019 ACR/ARP Annual Meeting
Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience
Muhammad Shipa¹, Anastasia-vasiliki Madenidou ², vera Choida ¹, Anna Radziszewska ³, corinne fisher ⁴, coziana ciurtin ¹, maria Leandro ¹ and Debajit Sen ¹, ¹Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, London, United Kingdom, ²Centre for Adolescent Rheumatology, University College London London, UK, LOndon, ³University College London, London, United Kingdom, ⁴Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, lonodn, United Kingdom
Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
Abstract Number: 1925 • 2019 ACR/ARP Annual Meeting
Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis
Francesca Ridella ¹, Giedre Januskeviciute ², Chiara Trincianti ³, Evert Hendrik Pieter Van Dijkhuizen ⁴, Gabriella Giancane ⁵, Serena Pastore ⁶, Kirsten Minden ⁷, Maria Ekelund ⁸, Patrizia Barone ⁹, Matilda Laday ¹⁰, Nicolino Ruperto ¹¹, Angelo Ravelli ¹² and Alessandro Consolaro¹³, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genova, Italy, ²Klaipeda Children's Hospital, Klaipeda, Lithuania, Klaipeda, Lithuania, ³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genoa, Italy, ⁴Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, ⁶Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy, Trieste, Italy, ⁷German Rheumatism Research Centre Berlin, and Charité University Medicine, Department of Rheumatology and Clinical Immunology, Berlin, Germany, Berlin, Germany, ⁸Ryhov County Hospital, Futurum - the Academy for health and care, Jonkoping, Sweden, Jonkoping, Sweden, ⁹Department of Pediatrics, University of Catania, Catania, Italy, Catania, Italy, ¹⁰Spitalul Clinic Județean De Urgenta, Tîrgu-Mures, Romania, Tîrgu-Mures, Romania, ¹¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹²IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy
Background/Purpose: The assessment of disease activity plays a pivotal role in the management of children with juvenile idiopathic arthritis (JIA). Most recent recommendations require that…
Abstract Number: 2718 • 2019 ACR/ARP Annual Meeting
A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis
Kiana Taba¹ and Elizabeth Ortiz ², ¹University of Southern California, LAGUNA HILLS, CA, ²LAC+USC/Keck Medicine of USC, Los Angeles
Background/Purpose: The use of biologic DMARDs (bDMARDs) has vastly changed the treatment of autoimmune arthritis, both Rheumatoid Arthritis (RA) and polyarticular and oligoarticular Juvenile Idiopathic…
Abstract Number: 2405 • 2018 ACR/ARHP Annual Meeting
Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis
Joseph McDonald¹, Curtis Travers², Courtney McCracken², Steven Yeh³, Kelly A. Rouster-Stevens⁴, Patricia Vega-Fernandez⁴, Elaine Ramsay⁴, Sampath Prahalad⁴, Carolyn Drews-Botsch⁵ and Sheila Angeles-Han⁶, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁶Rheumatology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH
Background/Purpose: Pediatric chronic non-infectious uveitis can lead to ocular complications and vision loss. The ophthalmic clinical exam is primarily used to assess uveitis outcomes but…
Abstract Number: 2407 • 2018 ACR/ARHP Annual Meeting
New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
Mikhail Kostik, Ekaterina Gaidar, Maria Likhacheva, Eugenia Isupova, Irina Chikova, Margarita Dubko, Vera Masalova, Tatiana Likhacheva, Ludmila Snegireva, Tatiana Kornishina, Olga Kalashnikova and Vyacheslav Chasnyk, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The most often prescribed biologics…
Abstract Number: 2409 • 2018 ACR/ARHP Annual Meeting
Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study
Guillaume Montagu¹, Ellie Mevel¹, William FAHY², Linda Rossi-Semerano³, Elisabeth Solau-Gervais⁴, Sonia Tropé⁵ and Jean-David Cohen⁶, ¹Research, Unknowns, strategy and innovation consulting, PARIS, France, ²KOURIR, Paris, France, ³Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵149 avenue du Maine, ANDAR, Paris, France, ⁶IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France
Background/Purpose: Adherence to DMARDs such as methotrexate and biologics is critical for patients with Juvenile Idiopathic Arthritis (JIA). Notwithstanding, few studies exists on that topic…

« Previous Page
1
…
4
5
6
7
8
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].